Literature DB >> 16736284

Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment.

Fiona H Blackhall1, Sacha Howell, Bill Newman.   

Abstract

Increased understanding of how variants in genes encoding metabolising enzymes, transporters and receptors affect drug efficacy and toxicity, in parallel with advances in genotyping technology means that clinical pharmacogenetics is drawing tantalisingly close to reality. This review considers some of the pharmacogenetic variants that have been described that are relevant to the management of women with breast cancer and how these may soon translate into clinical practice.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16736284     DOI： 10.1007/s10689-005-3241-5

Source DB:  PubMed          Journal:  Fam Cancer        ISSN： 1389-9600            Impact factor:   2.375


  45 in total

1.  Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk.

Authors:  Katja Mitrunen; Vesa Kataja; Matti Eskelinen; Veli-Matti Kosma; Daehee Kang; Simone Benhamou; Harri Vainio; Matti Uusitupa; Ari Hirvonen
Journal:  Pharmacogenetics       Date:  2002-01

2.  Tailoring breast cancer treatment to genetic status: the challenges ahead.

Authors:  Mary B Daly
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

3.  Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.

Authors:  Susan Nowell; Carol Sweeney; Maria Winters; Angie Stone; Nicholas P Lang; Laura F Hutchins; Fred F Kadlubar; Christine B Ambrosone
Journal:  J Natl Cancer Inst       Date:  2002-11-06       Impact factor: 13.506

4.  Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.

Authors:  M J Edelman; H Quam; B Mullins
Journal:  Cancer Chemother Pharmacol       Date:  2001-08       Impact factor: 3.333

5.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Authors:  A Broeks; J H Urbanus; A N Floore; E C Dahler; J G Klijn; E J Rutgers; P Devilee; N S Russell; F E van Leeuwen; L J van 't Veer
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

6.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

7.  Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.

Authors:  Martin Widschwendter; Kimberly D Siegmund; Hannes M Müller; Heidi Fiegl; Christian Marth; Elisabeth Müller-Holzner; Peter A Jones; Peter W Laird
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Authors:  Iain R Hutcheson; Janice M Knowlden; Tracie-Ann Madden; Denise Barrow; Julia M W Gee; Alan E Wakeling; Robert I Nicholson
Journal:  Breast Cancer Res Treat       Date:  2003-09       Impact factor: 4.872

Review 9.  The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Authors:  Silvana Martino; Joseph Costantino; Michelle McNabb; John Mershon; Katherine Bryant; Trevor Powles; Roberta J Secrest
Journal:  Oncologist       Date:  2004

10.  Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.

Authors:  Gottfried E Konecny; Christoph Thomssen; Hans Joachim Lück; Michael Untch; He-Jing Wang; Walter Kuhn; Holger Eidtmann; Andreas du Bois; Sigrid Olbricht; Dieter Steinfeld; Volker Möbus; Gunter von Minckwitz; Suganda Dandekar; Lillian Ramos; Giovanni Pauletti; Mark D Pegram; Fritz Jänicke; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2004-08-04       Impact factor: 13.506
View more
  1 in total

1.  Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management.

Authors:  Sarah Rofaiel; Esther N Muo; Shaker A Mousa
Journal:  Pharmgenomics Pers Med       Date:  2010-09-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.